News | News By Subject | News by Disease News By Date | Search News

Gonorrhea News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News

News from Around the Web
This STD Could Get A Lot Harder To Treat, CDC Study     7/15/2016
Super-Gonorrhoea's Spread "Causing Huge Concern"     4/18/2016
"Super-Gonorrhoea" Outbreak In Leeds     9/18/2015
Gonorrhea Drug Resistance Recedes With New Drug Combo Approach, Lancet Study Reveals     6/11/2013
Gonorrhea's Growing Resistance to Antibiotics Concerns Centers for Disease Control and Prevention (CDC)     7/8/2011
Gonorrhea Getting Harder to Treat - Antibiotic Resistance Pushing Gonorrhea Toward Superbug Status, University of Chicago Study     11/1/2010
1930s Drug Slows Tumor Growth: Gonorrhea Medication Might Help Fight Cancer, Johns Hopkins University Study     11/9/2009
Centers for Disease Control and Prevention (CDC) Alarmed at Rise of Drug-Resistant Gonorrhea     4/13/2007
Gonorrhea Linked To Risk Of Male Bladder Cancer     1/10/2007
Many STD Patients Reinfected Within Months     10/17/2006
Gonorrhea Linked To Higher Prostate Cancer Risk     9/25/2006

Press Releases
Entasis And The Global Antibiotic Research & Development Partnership (GARDP) To Develop A New Treatment For Drug-Resistant Gonorrhea     7/7/2017
ETST Announces 60-Patient Clinical Prelaunch Study For Its MSN-2 Medical Device For The Diagnosis Of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aubé As New CEO & CSO, And Nickolas Tabraue As President     11/21/2016
Entasis To Present Data At IDWeek On ETX2514SUL, A Novel Drug Targeting Multidrug-Resistant Acinetobacter Baumannii Infections     10/28/2016
Entasis Announces Positive Phase 2 Data Of ETX0914 For The Treatment Of Gonorrhea     9/23/2016
Entasis Announces Positive Phase 2 Data Of ETX0914 For The Treatment Of Gonorrhea     9/22/2016
Entasis Therapeutics Announces Appointments To Its Scientific And Clinical Advisory Board     12/15/2015
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Reports On PK Profile Of A Single Oral Dose Of Delafloxacin In Support Of U.S. Phase 3 Gonorrhea Program     9/8/2014
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Demonstrate Delafloxacin's Potent And Rapid Antimicrobial Activity Against Neisseria Gonorrhoeae     9/8/2014
Cempra Initiates Phase 3 Clinical Trial In Patients With Uncomplicated Gonorrhea Infection     8/12/2014
Rib-X Pharmaceuticals, Inc. Presents Data Demonstrating Potent In Vitro Activity of Delafloxacin Against Drug-Resistant Gonorrhea     7/16/2013
Cempra Pharmaceuticals, Inc. Announces Positive Top-Line Results From Solithromycin Phase 2 Clinical Trial in Patients With Uncomplicated Urogenital Gonorrhea     10/4/2012
Gen-Probe Incorporated (GPRO) Receives FDA Marketing Clearance For Standalone APTIMA(R) Test To Detect Neisseria Gonorrhoeae     3/15/2005
Polydex Pharmaceuticals (POLXF) Release: Phase III Ushercell (Cellulose Sulfate) Trial For HIV Prevention Under Way     12/22/2004
U.S. FDA Clears Personal Lubricant For Marketing; New Product From Instead, Inc. Shows Promise For Women     9/9/2004
Digene (DIGE) Announces Receipt Of CE Mark Certification     12/3/2003